Biotech ArriVent Plunges 63% After Lung Cancer Trial Fails Primary Endpoint

ArriVent BioPharma (NASDAQ:AVBP) shares plummeted 63% after its Phase 3 FURVENT trial for firmonertinib in NSCLC failed to meet its primary endpoint of progression-free survival (PFS) by blinded independent central review 🔗.

Key details:

• Median PFS for the 240 mg dose was 11.0 months vs. 9.5 months for the control arm, but the p-value (0.0654) missed statistical significance 🔗.
• Secondary endpoints showed clinical benefit, including a 60% objective response rate for the 240 mg dose vs. 33% for control 🔗.
• CEO Bing Yao expressed disappointment, noting the lack of meaningful PFS improvement over chemotherapy 🔗.

This trial failure represents a significant setback for ArriVent and highlights the inherent risks in biotech drug development.